Ciltacabtagene Autoleucel Demonstrates Superior Progression-Free Survival in Patients With Relapsed, Refractory Multiple Myeloma

Source: Pharmacy Times articles

The international cohort study evaluated the safety, efficacy of BCMA-targeting agents ciltacabtagene autoleucel and idecabtagene vicleucel.
Read More